EPICS Therapeutics

Oncology Therapeutics · Exhibitions
Patents: 5No open roles listed
Data updated Nov 20, 2026Full reportReport a mistake
Lately:1 news story in 90 daysFollow changes →

Facts

as of Nov 20, 2026

EPICS Therapeutics pioneers best-in-class small-molecule modulators of RNA epigenetics, with lead program EP102, a METTL3 inhibitor now advancing in patients with solid tumors.

Legal name
EPICS Therapeutics SA
Register numbers
VAT BE0690759071 · KBO 0690759071
Official records
LEI 875500LY5TWB3RTQQO43
Sources: company registers, GLEIF, Wikidata, the company's site, Alion job postingsReport a mistake

Products

Products →

EPICS Therapeutics has 1 clinical trials on record, 1 under way.

Clinical trials
EP102 Safety and Efficacy in METTL3 Modulation in Advanced Solid Tumors
phase 1 · under way · 48 participants · Advanced Solid Tumor (Phase 1)
Jul 2025
Source: each app’s App Store and Google Play page (an app counts as the company’s when its developer site is on the company’s domain); the products its own site names.

EPICS Therapeutics in public registers.

Legal entity active
EPICS Therapeutics SA
Not checked
Sanctions lists
OFAC SDN, EU consolidated
No match
Phishing reports
OpenPhish, Phishing.Database
None
Layoff notices
US WARN notices on file
None
Patents
5
Full employer checkScam signs in adverts, mail records, visa registers, domain history
Sources: company registers, the Alion truth index, OFAC and EU sanctions lists, US WARN notices